{
  "docId": "019de075-2fc9-715d-b6e1-faa3fd3ed1eb",
  "docSlug": "be407bbae8f9e005c3f7268aea2b4f13",
  "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 34 slides",
  "authorId": "neurosense-therapeutics",
  "authorName": "NeuroSense Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 28,
  "pageCount": 34,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "Includes a team photo and a progress bar at the bottom indicating the current slide is the 'Summary' section.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-2fc9-715d-b6e1-faa3fd3ed1eb/28",
  "deckHref": "/decks/019de075-2fc9-715d-b6e1-faa3fd3ed1eb",
  "deckJsonHref": "/decks/019de075-2fc9-715d-b6e1-faa3fd3ed1eb.json",
  "deckAnchorHref": "/decks/019de075-2fc9-715d-b6e1-faa3fd3ed1eb#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.45,
        "x": 0.02,
        "y": 0.285
      },
      "kind": "image",
      "text": "Team photo",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a35e70a2-14a2-4a0e-b5a9-78ca5a546690",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.48,
        "x": 0.48,
        "y": 0.25
      },
      "kind": "list",
      "text": "Top-line results from ALS Phase 2b placebo-controlled clinical trial expected in Q4 2023; Novel combination therapy designed to address multiple disease targets; Promising efficacy signals observed from ALS Phase 2a clinical trial; Statistically significant biomarker data in Phase 2a clinical trial; Expedited regulatory pathway- orphan drug designation & 505(b)2; Strong pipeline with several upcoming catalysts",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c877325c-02fe-4269-bfbe-4153ffb9a779",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.96,
        "x": 0.02,
        "y": 0.94
      },
      "kind": "other",
      "text": "Progress bar: Intro, PrimeC, Pre-clinical, Phase 2a Results, Phase 2b, Summary",
      "attrs": null,
      "subkind": "unclassified",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "528f1680-d0a4-4635-a675-aeec6d861f6b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.45,
        "x": 0.07,
        "y": 0.08
      },
      "kind": "title",
      "text": "NRSN Highlights Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "909e4cef-c03d-44eb-8dea-0817e8aaffb0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "e7f90a02-c80d-40a2-bc90-08b219e91b28",
      "evidence": "This slide is titled 'NRSN Highlights Summary' and contains a bullet list of highlights, which is typical of an executive summary.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 34,
      "from": 5,
      "beatId": "e49a51a7-5d8f-48c6-bbde-aebd1ab25027",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents PrimeC as a potential solution to the problem of limited ALS treatment options.",
      "position": 2,
      "confidence": 0.9,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 34,
      "from": 5,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "c317ff20-e462-4b87-8745-365a96908ee6",
      "evidence": "The document outlines the development process and clinical trials for PrimeC.",
      "position": 1,
      "objective": "What are the key tasks that need to be done to develop PrimeC as a treatment for ALS?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.8,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}